Glyburide
- Generic Name
- Glyburide
- Brand Names
- Diabeta, Glucovance, Glynase, Amglidia
- Drug Type
- Small Molecule
- Chemical Formula
- C23H28ClN3O5S
- CAS Number
- 10238-21-8
- Unique Ingredient Identifier
- SX6K58TVWC
- Background
Glyburide is a second generation sulfonylurea used to treat patients with diabetes mellitus type II. It is typically given to patients who cannot be managed with the standard first line therapy, metformin. Glyburide stimulates insulin secretion through the closure of ATP-sensitive potassium channels on beta cells, raising intracellular potassium and calcium ...
- Indication
Glyburide is indicated alone or as part of combination product with metformin, as an adjunct to diet and exercise, to improve glycemic control in adults with type 2 diabetes mellitus.
- Associated Conditions
- Gestational Diabetes Mellitus (GDM), Glycemic Control, Type 2 Diabetes Mellitus
- Associated Therapies
- -
Safety Study of Pioglitazone Compared To Glyburide on Liver Function
- First Posted Date
- 2007-06-29
- Last Posted Date
- 2012-02-28
- Lead Sponsor
- Takeda
- Target Recruit Count
- 2120
- Registration Number
- NCT00494312
Do Sulphonylureas Preserve Cortical Function During Hypoglycaemia?
- Conditions
- First Posted Date
- 2007-05-14
- Last Posted Date
- 2007-05-14
- Lead Sponsor
- King's College Hospital NHS Trust
- Target Recruit Count
- 10
- Registration Number
- NCT00472875
- Locations
- 🇬🇧
King's College Hospital NHS Foundation Trust, London, United Kingdom
Effect of GlucoNorm vs Glyburide on Post-Prandial Hyperglycemia in Elderly Subjects With Type 2 Diabetes
- First Posted Date
- 2007-03-23
- Last Posted Date
- 2018-01-18
- Lead Sponsor
- University of British Columbia
- Target Recruit Count
- 30
- Registration Number
- NCT00451620
- Locations
- 🇨🇦
University of British Columbia, Vancouver, British Columbia, Canada
Effect of Liraglutide on Blood Glucose Control in Subjects With Type 2 Diabetes
- Conditions
- Interventions
- First Posted Date
- 2006-10-29
- Last Posted Date
- 2017-03-08
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 400
- Registration Number
- NCT00393718
- Locations
- 🇯🇵
Novo Nordisk Investigational Site, Tokyo, Japan
A Drug-Drug Interaction Study of GK Activator (2) and Glyburide in Patients With Type 2 Diabetes.
- Conditions
- Interventions
- First Posted Date
- 2006-10-17
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 18
- Registration Number
- NCT00388986
Insulin Glargine in Type 2 Diabetic Patients
- Conditions
- Interventions
- First Posted Date
- 2006-07-04
- Last Posted Date
- 2009-09-15
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 387
- Registration Number
- NCT00347100
- Locations
- 🇨🇳
Sanofi-Aventis, Beijing, China
A Study of Saxagliptin in Subjects With Type 2 Diabetes Who Have Inadequate Blood Sugar Control With Sulfonylureas
- Conditions
- Interventions
- First Posted Date
- 2006-04-12
- Last Posted Date
- 2015-05-04
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 768
- Registration Number
- NCT00313313
- Locations
- 🇺🇸
Stewart Medical Group, Alhambra, California, United States
🇺🇸Valley Research, Fresno, California, United States
🇺🇸Randall Shue, D.O., Los Angeles, California, United States
Study of Alogliptin Combined With Sulfonylurea in Subjects With Type 2 Diabetes Mellitus.
- Conditions
- Interventions
- First Posted Date
- 2006-02-03
- Last Posted Date
- 2012-02-03
- Lead Sponsor
- Takeda
- Target Recruit Count
- 500
- Registration Number
- NCT00286468
Diabetes Study With Rosiglitazone Monotherapy Versus Metformin Or Glyburide/Glibenclamide
- Conditions
- First Posted Date
- 2006-01-19
- Last Posted Date
- 2017-11-29
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 4426
- Registration Number
- NCT00279045
- Locations
- 🇬🇧
GSK Investigational Site, Wigan, United Kingdom
Efficacy and Safety of Insulin Aspart Versus Glibenclamide in Type 2 Diabetes
- Conditions
- First Posted Date
- 2005-12-21
- Last Posted Date
- 2023-11-02
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 9
- Registration Number
- NCT00267683
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.